Terray Therapeutics, a chemistry-first, AI-native biotech company, announced a key discovery milestone in its multi-target partnership with Bristol Myers Squibb (BMS).

 

The achievement leverages Terray’s EMMI platform, which fuses high-throughput chemical experimentation with computational analysis and a generative AI-driven drug discovery engine. The platform’s iterative approach integrates AI with an extensive library of quantitative, purpose-built structure-activity data to identify molecules capable of tackling complex drug discovery challenges.

 

“Our AI-driven platform discovers and optimizes novel molecules for the difficult-to-drug targets—the ones with no chemistry starting point,” said Jacob Berlin, CEO of Terray Therapeutics. “We are excited about our success together and look forward to further progressing our discovery efforts.”

 

Through the collaboration, Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities. The partnership combines rapid, iterative experimentation with advanced hardware, AI models, and scientific expertise, with the goal of developing new therapies for areas with significant unmet medical needs.